Patients achieving a reduction# in the rate of clinically significant exacerbations during the 12-month follow-up period
| Total population¶ | Population with one exacerbation or more in the pre-mepolizumab treatment period+ | |
| Subjects | 368 | 340 |
| ≥50–100% reduction | 247 (67) | 247 (73) |
| >0– <50% reduction | 52 (14) | 52 (15) |
| No change/increase | 66 (18) | 40 (12) |
| Missing§ | 1 (<1) | 1 (<1) |
Data are presented as n or n (%). #: based on 365 days prior to enrolment plus any exacerbations starting during run-in; ¶: denominator based on patients with data for historical exacerbations only (n=366); +: denominator based on patients with one historical exacerbation or more only (n=340); patients with zero historical exacerbations were excluded (n=26); §: one patient did not have data during the follow-up period and is therefore not included in any of the categories.